Fig. 7

THZ531 synergizes with clinically approved inhibitors of the EGFR, mTORC1 and ATR signalling pathways. PDO lines were exposed for 5 days to combined treatments with suboptimal doses of THZ531 (30 nM and 50 nM), (a,b,e,f) and Lapatinib (0.5 and 1 µM) (a), RAD001 (10 and 100 nM) (b), Celarasertib (1 and 2 µM) (e) and AZD7762 (100 nM) (f) or with suboptimal doses of RAD001 (10 nM) and Lapatinib (0.1 µM) (c) or RAD001 (10 nM) and Trametinib (1 and 5 µM) (d). Moreover, PDO lines were exposed with suboptimal doses of Celarasertib (1 µM) and Olaparib (0.1 and 1 µM) (g). Cell viability was assessed by CellTiter-Glo 3D Cell Viability Assay. Statistically significant differences are indicated by the P-values (*P < 0.05, **P < 0.01, ***P < 0.001). The calculated CI values for drug combination relative to the individual drugs are presented above the graphs. CI values less than 1 suggest synergism. All results are expressed as the mean ± SEM derived from technical triplicates